Feedback of Natacha’s internship about the matrix remodeling in Parkinson’s disease: an in vitro study

This is the end of the 6-month internship of Natacha in HCS Pharma, about the microenvironment modifications in Parkinson’s disease. Indeed, in vivo studies in the literature showed that the neuronal death in Parkinson’s disease involved Extracellular Matrix (ECM) modifications, including an increase in some components like collagen and a Read more…

Importance du microenvironnement dans les modèles cérébraux in vitro pour le criblage phénotypique

Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in vitro, qui ne prennent pas en compte le microenvironnement, composé par les cellules gliales et Read more…

Feedback to the annual congress of the SCMC (Societe Cerveau et Maladies Cerebrovasculaires – Brain and cerebrovascular diseases Society)

Elodie Vandenhaute (our project director), Véronique De Conto (our project leader in in vitro pharmacology) and Natacha Perrin (our trainee in neurosciences) were present at the annual SCMC (Société Cerveau et Maladies Cérébrovasculaires – The French Brain and Cerebrovascular Diseases Society) congress, which took place on the 16th of June Read more…

Importance of the microenvironment in cerebral in vitro models for phenotypic screening (Abstract of Veronique’s thesis)

About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…